Can Sionna Therapeutics, Inc. Common Stock cover its short-term obligations?

Its current ratio is 22.60 — current assets exceed current liabilities.

Where does Sionna Therapeutics, Inc. Common Stock's balance sheet data come from?

Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Sionna Therapeutics, Inc. Common Stock SION Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24
Cash and cash equivalents	$59.41M+53.3%	$38.75M-1.9%
Restricted cash	$963K+0.1%	$962K—
Prepaid expenses and other current assets	$17.73M+215%	$5.63M—
Total current assets	$241.42M+59.9%	$150.99M—
Property and equipment, net	$2.23M-9.8%	$2.47M—
Accumulated depreciation	$2.12M+35.1%	$1.57M—
Operating lease right-of-use assets	$6.93M-11.6%	$7.83M—
Other non-current assets	$0-100%	$2.99M—
Long-term investments	$74.42M+263%	$20.51M—
Available-for-sale securities	——	——
Total assets	$325.95M+75.5%	$185.75M—
Accounts payable	$8.18M—	——
Accrued expenses	$4.74M—	$0—
Operating lease liabilities, current	$1.27M+18.4%	$1.07M—
Total current liabilities	$11.71M+12.4%	$10.42M—
Operating lease liabilities, non-current	$7.41M-14.6%	$8.68M—
Operating Lease Liabilities (Total)	$8.68M—	——
Total liabilities	$19.12M+0.1%	$19.1M—
Preferred stock	$0—	$0—
Common stock	500M+9,999,900%	5K—
Additional paid-in capital	$562.6M+3,209%	$17M—
Retained earnings	-$256.35M-41.6%	-$181.09M—
Accumulated other comprehensive income (loss)	$540K+46.7%	$368K—
Total stockholders' equity	$306.83M+287%	-$163.71M-42.5%
Total liabilities and stockholders' equity	$325.95M+75.5%	$185.75M—
Available-for-Sale Debt Securities	$177.43M+61.7%	$109.75M—
Available-for-Sale Debt Securities - Amortized Cost	$251.31M+93.5%	$129.89M—
Cash Cash Equivalents And Short Term Investments	——	——
Debt securities - current	$177.43M+61.7%	$109.75M—
Deferred Tax Assets and Other Non-Current Assets	$0-100%	$2.99M—
Net Investment in Lease	$6.93M-11.6%	$7.83M—
Long-term marketable securities	$74.16M+264%	$20.4M—
Operating lease right-of-use assets	$6.93M-11.6%	$7.83M—
Other non-current assets	$0-100%	$2.99M—
Property, plant and equipment at cost	$4.35M+7.7%	$4.04M—
Operating Lease Right-of-Use Assets in Other Assets	$6.93M-11.6%	$7.83M—
Software and Technology Licenses, Net	$0-100%	$2.99M—
Accrued Manufacturing Costs	$4.74M+59.5%	$2.97M—
Other Commercial Liabilities	$9.67M+18.5%	$8.16M—
Accrued Liabilities, Current	$9.67M+18.5%	$8.16M—
Compensation and benefits	$4.74M+59.5%	$2.97M—
Other accrued liabilities	$6K—	$0—
Professional Service Fees Payable	$522K-29.2%	$737K—
Total debt	$8.68M-11.0%	$9.75M—
Common Stock Par Value Per Share	$0.000.0%	$0.00—
Common Stock Shares Issued	44.7M+832%	4.8M—
Convertible Preferred Stock Authorized Shares	10M—	0—
Convertible Preferred Stock Issued Shares	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$45K+800%	$5K—
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—
Number of Exercisable Options	——	——
Preferred Stock Par Value Per Share	$0.000.0%	$0.00—
Share-Based Payment Award Options Outstanding - Number	5.8M+55.9%	3.7M—
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——
Weighted Average Exercise Price of Outstanding Options	$12.01+105%	$5.87—
Cumulative Cost Basis	$4.35M+7.7%	$4.04M—
Accrued deferred offering costs	$0—	——
Professional service fees	$522K-29.2%	$737K—
Accrued research and development	$4.31M+8.7%	$3.96M—
Common stock, par value (in dollars per share)	$00.0%	$0—
Common stock, shares authorized (in shares)	$500M+806%	$55.2M—
Common stock, shares issued (in shares)	$44.72M+832%	$4.8M—
Common Stock, Shares, Outstanding	$44.72M+847%	$4.72M—
Available-for-sale securities, allowance for credit loss	——	——
Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss	$251.31M+93.5%	$129.89M—
Investments	$177.15M+61.8%	$109.49M—
Estimated Fair Value	$251.85M+93.4%	$130.26M—
Cost not yet recognized	——	——
Other accrued liabilities	$101K—	$0—
Preferred Stock, Par or Stated Value Per Share	$00.0%	$0—
Preferred Stock, Shares Authorized	$10M—	$0—
Preferred Stock, Shares Issued	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$5.77M+55.9%	$3.7M—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$12.01+105%	$5.87—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——
Balance	$168.01M+917%	$16.52M—
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Sionna Therapeutics, Inc. Common Stock cover its short-term obligations?: Its current ratio is 22.60 — current assets exceed current liabilities.
Where does Sionna Therapeutics, Inc. Common Stock's balance sheet data come from?: Every line is extracted from Sionna Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.